![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Department of Physics, Florida International University, Miami, FL 33199,
* Department of Chemistry, Florida International University, Miami, FL 33199 and
Applied Food Biotechnology, Inc., O’Fallon, MO 63366
3To whom correspondence should be addressed. E-mail: bone{at}fiu.edu.
 |
ABSTRACT |
|---|
 TOP ABSTRACT SUBJECTS AND METHODSRESULTSDISCUSSIONLITERATURE CITED |
|---|
5 x 10-7 mol/L. The rate of increase in macular pigment optical density was correlated with the plateau concentration of carotenoids in the serum (r = 0.58, P < 0.001), but not with the presupplementation optical density (r = 0.13, P = 0.21). The mean rate of increase was (3.42 ± 0.80) x 105 mAU/d per unit concentration (mol/L) of carotenoids in the serum. It remains to be demonstrated whether lutein or zeaxanthin dietary supplements reduce the incidence of AMD.
KEY WORDS: • macular pigment • lutein • zeaxanthin • carotenoids • age-related macular degeneration
Current interest in the human macular pigment (MP), consisting of lutein (L) and zeaxanthin (Z), is driven largely by its possible association with a reduced risk for age-related macular degeneration (AMD). Many dietary supplements consisting of, or containing, these carotenoids are now commercially available, promoted for their supposed benefits to the health of the eye. Over the course of several years, during which preparations of L and Z have become available for human consumption, we investigated their effects on MP density and on their concentration in the blood serum. The purpose of the present study was to consolidate our findings and determine whether any unifying conclusions could be drawn from them.
The macula lutea, or yellow spot, which characterizes the primate retina, is named for the region in and around the fovea where L and Z are concentrated (1 ). These carotenoids appear mainly in the photoreceptor axon layer with an L/Z ratio of about 0.5 (2 ,3 ). At eccentricities beyond 1–2 mm from the fovea, the pigments are still present, though no longer visible, with an L/Z ratio of about 2.0 (3 ). In recent studies, L and Z have been found in the rod outer segments and retinal pigment epithelium of both the perifoveal and peripheral retina (4 ,5 ).
The central region of the retina is prone to the destructive effects of AMD, a leading cause of vision loss in the United States (6 ). The photooxidative processes by which blue light in particular may contribute to the etiology of AMD have been described by Schalch et al. (7 ). Remarkably, the wavelengths of light that damage the retina are essentially limited to the same range (400–500 nm) where MP absorbs most strongly (8 ). MP peak optical density (at 460 nm) in the central 1–2° lies in the range of 0.1 to 0.9 for most people (9 ,10 ). Thus, for a person having an optical density at the low end of this range, structures posterior to the MP will be exposed to approximately six times the blue light flux compared with those of a person at the other extreme. As a result, we might expect a greater incidence of AMD among people having a low MP density. Interestingly, in the advanced form of AMD known as geographic atrophy, the foveal center, which contains the highest concentrations of L and Z, tends to be spared until late in the course of the disease (11 ,12 ).
In addition to an ability to attenuate blue light and thereby reduce photooxidation, L and Z are effective quenchers of singlet oxygen and reactive radicals (13 ). In this capacity, too, they can limit photooxidative processes, but only if they are in close proximity to the sites where oxidation may be occurring. The discovery of L and Z in the rod outer segments is of particular relevance in this regard (4 ,5 ).
There is evidence to support the hypothesis that MP provides protection against AMD. The Eye Disease Case-Control Study Group (EDCCSG) reported significant associations between high levels of L and Z in both the diet and serum of their subjects and a reduced risk of advanced, neovascular AMD (14 ,15 ). However, the Beaver Dam Study reported only slightly, and nonsignificantly, lower concentrations of serum L and Z in AMD subjects in comparison with controls (16 ). This may have been attributable to the relatively low intake of L and Z by these subjects compared with those in the EDCCSG study. In another study, L and Z concentrations in autopsy retinas from donors with and without AMD were compared. A significant trend for reduction in risk for AMD with increasing amounts of L and Z was noted (17 ). In a representative sample of the U.S. population, levels of lutein in the diet, but not the serum, were related to later, but not early, stages of AMD (18 ). However, these relationships were limited to subjects who were in the younger age categories at risk for these conditions. Unfortunately, the question of causality between L and Z levels and risk of AMD cannot be answered by these studies.
To investigate directly the efficacy of L and Z as prophylactics against AMD, intervention trials will be required. Because AMD is a disease that may be the final manifestation of a lifetime of contributory factors, such trials would necessarily be long term. A practical consideration, before the implementation of such a study, is the extent to which MP density can be increased through dietary modification that increases the intake of L and/or Z. Previous studies have focused primarily on the effects of single fixed dosages of L (19 –24 ). In this study we compared the effects of L and Z dietary supplements, the former in a range of dosages, on the serum and the MP. We hypothesized that the blood serum level of L or Z would be correlated with the dose, and the increase in MP density would be correlated with the blood serum level of L and Z resulting from the supplement. We also hypothesized that the increase in MP density would be correlated with the presupplementation MP density.
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTSUBJECTS AND METHODSRESULTSDISCUSSIONLITERATURE CITED |
|---|
Subjects over the age of 18 y, and of either sex, were recruited from the University community. Having been informed of the nature of the study, the subjects signed an informed consent form approved by the Institutional Review Board. Subjects were given individual training in flicker photometry, the technique used to measure MP optical density. (See below.) Only if they demonstrated proficiency in the task and were able to give reproducible results were they accepted into the study. Approximately 90% of the screened subjects met the proficiency criterion. Those who failed tended to be older subjects with little or no scientific training. Each subject accepted into the study was given a full eye exam by an ophthalmologist to ensure that no pathologies were present. The only other eligibility requirement was (self-identified) good health.
Supplementation
Experiment 1.
The first available L supplement was made using an oleoresin containing natural L esters extracted from marigolds. The response to this supplement was reported previously (19
), and the main outcome is included here for comparison purposes only. In brief, 30 mg doses of L equivalent were prepared, each being suspended in 2 mL of canola oil. Two subjects, A and B, took the 30 mg daily dose for 140 d. The normal daily intake of L and Z in the United States is reported to be about 1 to 1.5 mg/d, and the L/Z ratio in the diet is about 4 or 5. Consequently, the 30 mg dose represents 20 to 30 times the normal daily intake. It should also be noted that marigold extracts contain small amounts of Z, 5% of the amount of L.
Experiment 2. Sufficient Z for two subjects was subsequently made available, crystalline, unesterified and encapsulated in gelatin/starch beadlets. The source of the Z was a commercial culture of Flavobacteria. Subject A and a new subject C took the supplement for 120 and 60 d, respectively. The daily dose was again 30 mg, suspended in 2 mL of canola oil, and represents about 100 times the average daily intake of Z. The last day of L supplementation for subject A preceded the 1st d of Z supplementation by 21 mo.
Experiment 3. The next supplement to be tested was a commercially produced gel capsule containing 1.2 mg of L, as esters, from marigolds. In addition, each capsule contained a number of herbal extracts including docosahexanoic acid, bilberry extract, lemon flavonoid concentrate and acerola concentrate. Twenty-one subjects took two capsules/d (2.4 mg of L) for 6 mo. The purpose of this experiment was to investigate the effects of a dose that provided a similar amount of L to that found in the average U.S. diet.
Experiment 4. The final supplements that we investigated consisted of gel capsules containing either 5 or 20 mg of L (as esters from marigolds), together with a small quantity of vegetable oil. Twelve subjects took 20 mg/d, and two subjects took 5 mg/d, for 120 d.
During all four studies, subjects were instructed to follow their normal, self-selected diet and to take the L or Z supplement with a meal, or shortly thereafter.
Macular pigment measurements
MP optical densities were determined psychophysically using the well-established technique of heterochromatic flicker photometry (19 ). The subject viewed a 1.5° circular stimulus that alternated at about 30 Hz between 460 nm, the wavelength of maximum MP absorbance, and 540 nm, where the absorbance is essentially zero. While fixating on the center of the stimulus, the subject adjusted the 460-nm intensity to produce a flicker null. A subject with a denser MP would need a higher intensity to compensate for the attenuation that the pigment produces. To account for differences among subjects in relative cone populations and/or lens absorption, both of which will affect the intensity setting, a second setting was made at about 15 Hz with the stimulus imaged 8° above the fovea. At this location, MP absorbance is essentially zero. The log ratio of intensity settings is equal to the MP optical density at 460 nm.
The subjects made 5–10 sequential settings each for the central and peripheral locations of the stimulus. Measurements were made in both eyes before, during and after the supplementation period, and were repeated on separate days at least twice/wk.
Serum analysis
Blood samples were obtained from the subjects during the study period to monitor changes in carotenoid concentration. Generally, at least two samples were obtained in the 2 wk preceding supplementation, and at least one sample was obtained every 2 wk during supplementation. Finally, three samples were obtained in the 2 wk after supplementation. Subjects were not required to follow a more rigid schedule than this, nor were the blood sampling days related to flicker photometry sessions. For expts. 1 and 2, blood sampling was more frequent and flicker photometry was conducted 3–5 times/wk. Subject C (expt. 2), unfortunately, elected to leave the study after 60 d of Z supplementation, so no postsupplementation data are available. The subject became increasingly uncomfortable with venipuncture.
Blood samples were collected in VacutainerTM serum separator tubes with no anticoagulant, and allowed to stand for 30 min to allow for coagulation. The samples were centrifuged for 10 min and the serum removed by pipette. Carotenoids were extracted from the serum by established techniques (25 ). For quantification purposes, 20 µL of an ethanol solution containing 90 ng of monohexyl lutein ether were added to each 200 µL of serum as an internal standard. To precipitate proteins, 2 mL of ethanol/water (50:50) were also added. To extract the carotenoids, 2 mL of hexane were added and the mixture vortexed for 1 min followed by centrifuging for 5 min. The hexane layer was removed and the extraction step repeated twice more. The pooled hexane was evaporated to dryness under a stream of nitrogen before analysis of the extract by HPLC.
HPLC was carried out on a reversed-phase system using a 250 x 4.6 mm Ultracarb ODS 3-µm column (Phenomenex, Torrance, CA). The mobile phase was acetonitrile/methanol (85:15) with 0.1% triethylamine added to inhibit degradation of carotenoids. The flow rate was 1 mL/min and detection was at 451 nm. The amounts of L and Z were determined by comparing their chromatogram peak areas with that of the internal standard.
Statistical analyses
Results are expressed as means ± SD. Increases in serum concentrations of L and Z, and increases in MP density resulting from supplementation were tested for significance using an independent-samples t test (
= 2). Values of P < 0.05 were considered significant. Whether rates of increase in MP density resulting from supplementation were significantly different from zero was determined by use of a one-sample t test ( = 2). Again, values of P < 0.05 were considered significant. Adjustments for other potentially influencing factors, such as body mass index, were not included in the analyses. We also applied a multiple linear regression model to the rate of increase in MP optical density using the elevated serum concentration of L and Z and the presupplementation optical density as independent variables.
|
RESULTS |
|---|
|
TOPABSTRACTSUBJECTS AND METHODSRESULTSDISCUSSIONLITERATURE CITED |
|---|
Because expt. 1 (30 mg/d of L) was previously reported elsewhere (19
), the similar results of expt. 2 (30 mg/d of Z) are described first. Subject A was a 53-y-old male and subject C was a 21-y-old male. Both subjects responded to the Z supplement, with 5- to 6-fold increases in serum Z concentration. For subject A, Z concentration increased from 0.097 x 10-6 mol/L before supplementation to a plateau at 0.56 x 10-6 mol/L over 30 d (Fig. 1
). For subject C, the increase from 0.086 x 10-6 mol/L to a plateau at 0.48 x 10-6 mol/L was similar though much more rapid, occurring in 10 d. Upon discontinuing the Z supplement, the serum concentration of Z in subject A dropped roughly exponentially to near presupplementation levels over 20 d (Fig. 1)
. As stated earlier, no postsupplementation serum data are available for subject C.
|
70 d period before supplementation. Thereafter, the optical densities increased in a more or less linear fashion at mean rates of 0.71 ± 0.08 and 0.56 ± 0.09 mAU/d in the left and right eyes, respectively (AU = absorbance unit). This trend continued throughout the 120-d supplementation period, and during the 20 d following, before leveling off. Measurements made during the succeeding 100 d showed no tendency to decline. For this subject, significant differences in optical densities between left and right eyes were maintained throughout the study period. The eyes of subject C were more closely matched. Presupplementation MP optical densities were 0.567 and 0.538 AU in the left and right eyes, respectively. After 25 d of supplementation, rates of increase in optical density of about 0.35 and 0.31 mAU/d were observed in the left and right eyes, respectively.
|
Subject B was a 42-y-old male. Subjects A and B responded more robustly in both serum and retina to the 30 mg/d L supplement than did subjects A and C to the 30 mg/d Z supplement. Because the supplements were equal in amount, the pertinent features of the serum and retina responses are compared in Table 1 and Table 2 , respectively.
|
|
The results of this experiment will be reported fully elsewhere. The study group consisted of 17 females and 4 males ranging in age from 19 to 59 y with a mean of 28 ± 10 y. In summary, for all 21 subjects taking 2.4 mg of L/d, a significant increase in serum L was observed (P < 0.05), as determined by an independent-samples t test. The t test compared the mean serum L concentration for each subject before supplementation with the mean plateau concentration during supplementation. The serum L concentration for the group before supplementation was (0.245 ± 0.120) x 10-6 mol/L, and the plateau concentration was (0.484 ± 0.176) x 10-6 mol/L The increases in serum L concentration determined in this way ranged from 20 to 300%, with a mean for the group of 100%. Complete MP optical density measurements were obtained from 20 of the 21 subjects. Over the 6-mo supplementation period, significant increases in MP optical density, as determined by an independent-samples t test, occurred in 12 subjects (P < 0.0005 to P < 0.05). Marginally significant increases occurred in three subjects (P < 0.1), and no significant changes occurred in the remaining five subjects (P 
0.18). The mean increase for all 20 subjects was 10%, representing an increase from 0.443 ± 0.173 AU before supplementation to a postsupplementation value of 0.489 ± 0.174 AU.
Experiment 4.
The two subjects taking 5 mg of L/d were females ages 26 and 27 y. Their plateau concentrations of serum L were 0.74 x 10-6 and 1.14 x 10-6 mol/L, respectively. The mean rates of increase in MP optical density, averaged for both eyes, were 0.303 and 0.219 mAU/d, respectively. In one eye of the former subject, the rate of increase tended to be significantly different from zero (P < 0.1), but in the other eye, it did not (P = 0.42), as determined by one-sample t tests. Significant rates of increase were observed in both eyes of the other subject (P < 0.005 and P < 0.02). Of the 12 subjects taking 20 mg/d of L, eight were female and four were male. Their ages ranged from 19 to 60 y, with a mean of 37 ± 15 y. The serum concentrations that were achieved ranged from 0.77 x 10-6 to 2.45 x 10-6 mol/L, with a mean of (1.30 ± 0.44) x 10-6 mol/L. The mean rates of increase in MP optical density, averaged for both eyes, ranged from 0.055 to 1.56 mAU/d. The mean for the group was 0.53 ± 0.41 mAU/d. An example of a responding subject is shown in Figure 3
. In three subjects, the rates of increase in MP optical density for both eyes were not different from zero, as determined by a one-sample t test (P 0.18). An example of one of these three nonresponding subjects is shown in Figure 4
.
|
|
|
|
|
DISCUSSION |
|---|
|
TOPABSTRACTSUBJECTS AND METHODSRESULTSDISCUSSIONLITERATURE CITED |
|---|
The regression line in Figure 5
does not include the two data points (open circles) for the (30 mg/d) Z-supplemented subjects. The Z concentrations at the plateau were anomalously low compared with those achieved with the 30 mg/d L supplements. For subject A, who participated in both experiments, the serum concentration of Z achieved in expt. 2 was only about one third of the serum concentration of L achieved in expt. 1. It is unlikely that this reflects an efficiency of uptake of Z into the serum that was lower than that for L. The L/Z ratio in serum generally reflects the ratio found in the average diet (4:1). In addition, Neuringer et al. (28
) studied monkeys that were supplemented with either pure L or pure Z. They found that, although serum levels of L rose faster than those of Z, by 16 wk, both had stabilized at comparable concentrations of 0.8 x 10-6 mol/L. An alternative explanation is that the lower bioavailability that we found for Z may be the result of the formulation of the product. The L was esterified and prepared as an oleoresin that was easily solubilized in vegetable oil before consumption. The Z was crystalline, unesterified and incorporated in gelatin/starch beadlets, and exhibited little or no tendency to dissolve in vegetable oil.
The factors that influence the transport of L and Z into the serum are presumed to be different from those that influence their subsequent transfer from the serum into the retinal tissues. Our hypothesis that the concentration of L and Z in the serum would be a major factor for this latter transfer was supported by the data. Because of the different periods of supplementation (60 d to 6 mo), rates of increase in MP optical density, rather than absolute increases, were plotted as a function of the plateau concentration of combined L and Z in the serum (Fig. 6) . Approximately one third of the variance in the rate of increase in MP optical density could be attributed to a linear dependency on the plateau concentration (Fig. 6) . Another factor that might be expected to affect the rate of increase in MP optical density is the presupplemention MP optical density. If the accumulation of L or Z in the macula eventually reaches a saturation level, we might expect a slower rate of increase of optical density in subjects whose density is already high. Conversely, a high density may be an indication that the subject readily absorbs L and Z into the retina. If that were the case, such subjects might be expected to respond with the higher rates of increase in MP optical density. However, analysis of the data indicated that presupplementation MP optical density was not a significant factor in determining the rate of increase in MP optical density (r = 0.13, P = 0.21).
The high rate of nonresponse of MP optical density among subjects who consumed the low L dosage (2.4 mg/d) is not altogether unexpected. The dose is somewhat higher than the average daily intake for the U.S. population, but still less than half of the daily intake of those in the upper quintile reported by the EDCCSG (14 ). No subject characteristic (age or gender) distinguished the responders from the nonresponders, but this is not surprising, given that most of the subjects in this group were young (under 30 y) and female. For this group, considered separately, the correlation between the rate of increase in MP optical density and the serum plateau concentration of L and Z was not significant.
Subject A’s MP optical density began to level off at the same time that the serum concentration of Z returned to baseline, as indicated in Figure 2 . The tendency for the postsupplementation optical density to remain elevated was previously observed for both subjects A and B in the earlier L study (expt. 1) (19 ), and was also reported by others (23 ). It reinforces the suggestion, made at the time, that there may be a very slow turnover of carotenoids in the retina. Carotenoids are generally unstable in the presence of heat, light and oxygen (29 ), but it is possible that they achieve a high level of stability when incorporated into the retinal tissues. If this is the case, continued high dosing with L or Z may not be necessary to maintain a high density of MP. Rather, a high dose could be employed initially to produce a timely increase in MP density; thereafter, a lower maintenance dose may be adequate to prevent any decrease from occurring. This statement is made with the realization that the beneficial effects of high MP density are tentative. Although there is compelling evidence for an association between the presence of L and Z in the diet, serum and eyes of individuals, and reduced risk of AMD, the association has not been demonstrated to be causal (14 ,15 ,17 ). The concept of L and Z acting as markers for some underlying factor, which is itself responsible for the disease, remains a possibility.
In summary, all subjects receiving L doses in the range 2.4– 30 mg/d, and both subjects receiving 30 mg/d of Z, responded to the supplement with significant, but varied, increases in the serum concentration of that carotenoid. Many subjects also responded with increases in the density of their macular pigment. Subjects who did not respond tended to be those who consumed the lower dosages, which generally produced lower serum concentrations of carotenoids.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
2 Presented in part in abstract form at the annual meeting of the Association for Research in Vision and Ophthalmology, April 29– May 4, 2001, Fort Lauderdale, FL. [Bone, R. A., Landrum, J. T., Llerena, C. M., Ruiz, C. A. & Tibor, S. (2001) Dependence of macular pigment density increases on elevated serum levels of lutein and zeaxanthin resulting from supplementation. Invest. Ophthalmol. Vis. Sci. 42: S233.]
4 Abbreviations used: AMD, age-related macular degeneration; EDCCSG, Eye Disease Case-Control Study Group; L, lutein; MP, macular pigment; OD, optical density; Z, zeaxanthin.
Manuscript received 4 October 2002. Initial review completed 1 November 2002. Revision accepted 31 December 2002.
|
LITERATURE CITED |
|---|
|
TOPABSTRACTSUBJECTS AND METHODSRESULTSDISCUSSIONLITERATURE CITED |
|---|
1. Bone, R. A., Landrum, J. T. & Tarsis, S. L. (1985) Preliminary identification of the human macular pigment. Vision Res. 25:1531-1535.[Medline]
2. Snodderly, D. M., Auran, J. D. & Delori, F. C. (1984) The macular pigment II. Spatial distribution in primate retinas. Invest. Ophthalmol. Vis. Sci. 25:674-685.
3. Bone, R. A., Landrum, J. T., Fernandez, L. & Tarsis, S. L. (1988) Analysis of macular pigment by HPLC: retinal distribution and age study. Invest. Ophthalmol. Vis. Sci. 29:843-849.
4. Sommerburg, O. G., Seims, W. G., Hurst, J. S., Lewis, J. W. & van Kuijk, F.J.G.M. (1999) Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr. Eye Res. 19:491-495.[Medline]
5. Rapp, L. M., Maple, S. S. & Choi, J. H. (2000) Lutein and zeaxanthin concentrations in rod outer segment membranes from perifoveal and peripheral human retina. Invest. Ophthalmol. Vis. Sci. 4:1200-1209.
6. Hyman, L. (1992) Epidemiology of AMD. Hampton, G. R. Nelson, D. T. eds. Age-Related Macular Degeneration: Principles and Practice 1992:1-35 Raven Press New York, NY. .
7. Schalch, W., Dayhaw-Barker, P. & Barker, F. M., II (1992) The carotenoids of the human retina. Taylor, A. eds. Nutritional and Environmental Influences on the Eye 1992:215-250 CRC Press Boca Raton, FL. .
8. Ham, W. T. & Mueller, W. A. (1989) The photopathology and nature of the blue-light and near-UV retinal lesion produced by lasers and other optical sources. Wolbarsht, M. L. eds. Laser Applications in Medicine and Biology 1989:191-246 Plenum Press New York, NY. .
9. Werner, J. S., Donnelly, S. K. & Reinhold, K. (1987) Aging and human macular pigment density. Appended with translations from the work of Max Schultze and Ewald Hering. Vision Res. 27:257-268.[Medline]
10. Bone, R. A. & Sparrock, J.M.B. (1971) Comparison of macular pigment densities in human eyes. Vision Res. 11:1057-1064.[Medline]
11. Schatz, H. & McDonald, H. R. (1989) Atrophic macular degeneration. Rate of spread of geographic atrophy and visual loss. Ophthalmology 96:1541-1551.[Medline]
12. Sunness, J. S., Bressler, N. M., Tian, Y., Alexander, J. & Applegate, C. A. (1999) Measuring geographic atrophy in advanced age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 40:1761-1769.
13. Palozza, P. & Krinsky, N. I. (1992) Antioxidant effects of carotenoids in vivo and in vitro: an overview. Packer, L. eds. Methods in Enzymology 213:403-420 Academic Press San Diego, CA. .[Medline]
14. Seddon, J. M., Ajani, U. A., Sperduto, R. D., Hiller, R., Blair, N., Burton, T. C., Farber, M. D., Gragoudas, E. S., Haller, J., Miller, D. T., Yannuzzi, L. A. & Willett, W. (1994) Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. J. Am. Med. Assoc. 272:1413-1420.
15. Eye Disease Case-Control Study Group (1993) Antioxidant status and neovascular age-related macular degeneration. Arch. Ophthalmol. 111:104-109.
16. Mares-Perlman, J. A., Brady, W. E., Klein, R., Klein, B. E., Bowen, P., Stacewicz-Sapuntzakis, M. & Palta, M. (1995) Serum antioxidants and age-related macular degeneration in a population-based case-control study. Arch. Ophthalmol. 113:1518-1523.
17. Bone, R. A., Landrum, J. T., Mayne, S. T., Gomez, C. M., Tibor, S. E. & Twaroska, E. E. (2001) Macular pigment in donor eyes with and without AMD: a case-control study. Invest. Ophthalmol. Vis. Sci. 42:235-240.
18. Mares-Perlman, J. A., Fisher, A. I., Klein, R., Palta, M., Block, G., Millen, A. E. & Wright, J. D. (2001) Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 153:424-432.
19. Landrum, J. T., Bone, R. A., Joa, H., Kilburn, M. D., Moore, L. L. & Sprague, K. E. (1997) A one year study of the macular pigment: effect of 140 days of a lutein supplement. Exp. Eye Res. 65:57-62.[Medline]
20. Duncan, J. L., Aleman, T. S., Gardner, L. M., De Castro, E., Marks, D. A., Emmons, J. M., Bieber, M. L., Steinberg, J. D., Bennett, J., Stone, E. M., MacDonald, I. M., Cideciyan, A. V., Maguire, M. G. & Jacobson, S. G. (2001) Macular pigment and lutein supplementation in choroideremia. Exp. Eye Res. 74:371-381.
21. Garnett, K. M., Guerra, L. H., Lamb, J. D., Epperson, J. L., Greenbury, D. L., Dorey, K. & Craft, N. E. (2002) Serum and macular pigment responses to supplementation with lutein or zeaxanthin. Assoc. Res. Vis. Ophthalmol. 43:2820(abs.).
22. Aleman, T. S., Duncan, J. L., Bieber, M. L., DeCastro, E., Marks, D. A., Gardner, L. M., Steinberg, J. D., Cideciyan, A. V., Maguire, M. G. & Jacobson, S. G. (2001) Macular pigment and lutein supplementation in retinitis pigmentosa and Usher syndrome. Invest. Ophthalmol. Vis. Sci. 42:1873-1881.
23. Hammond, B. R., Jr, Johnson, E. J., Russel, R. M., Krinsky, N. I., Yeum, K.-J., Edwards, R. B. & Snodderly, D. M. (1997) Dietary modification of human macular pigment density. Invest. Ophthalmol. Vis. Sci. 38:1795-1801.
24. Olmedilla, B., Granado, F., Blanco, I., Vaquero, M. & Cajigal, C. (2001) Lutein in patients with cataracts and age-related macular degeneration: a long-term supplementation study. J. Sci. Food Agric. 81:904-909.
25. Giuliano, A. R., Matzner, M. B. & Canfield, L. M. (1993) Assessing variability in quantitation of carotenoids in human plasma: variance component model. Packer, L. eds. Methods in Enzymology 214:94-101 Academic Press San Diego, CA. .[Medline]
26. Bone, R. A., Landrum, J. T., Dixon, Z., Chen, Y. & Llerena, C. M. (2000) Lutein and zeaxanthin in the eyes, serum and diet of human subjects. Exp. Eye Res. 71:239-245.[Medline]
27. Rock, C. L., Thornquist, M. D., Neuhouser, M. L., Kristal, A. R., Neumark-Sztainer, D., Cooper, D. A., Patterson, R. E. & Cheskin, L. J. (2002) Diet and lifestyle correlates of lutein in the blood and diet. J. Nutr. 132:525S-530S.
28. Neuringer, M., Johnson, E. J., Snodderly, D. M., Sandstrom, M. M. & Schalch, W. (2001) Supplementation of carotenoid-depleted rhesus monkeys with lutein or zeaxanthin: effects on serum and adipose tissue carotenoids and macular pigment. Assoc. Res. Vis. Ophthalmol. 42:1209(abs.).
29. Pfander, H. (1993) Carotenoids: an overview. Packer, L. eds. Methods in Enzymology 213:3-13 Academic Press San Diego, CA. .
This article has been cited by other articles:
|
|
 |
|
  R. Vishwanathan, E. F Goodrow-Kotyla, B. R Wooten, T. A Wilson, and R. J Nicolosi Consumption of 2 and 4 egg yolks/d for 5 wk increases macular pigment concentrations in older adults with low macular pigment taking cholesterol-lowering statins Am. J. Clinical Nutrition, November 1, 2009; 90(5): 1272 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Karpa, P. Mitchell, K. Beath, E. Rochtchina, R. G. Cumming, and J. J. Wang Direct and Indirect Effects of Visual Impairment on Mortality Risk in Older Persons: The Blue Mountains Eye Study Arch Ophthalmol, October 1, 2009; 127(10): 1347 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Moeller, R. Voland, G. E. Sarto, V. L. Gobel, S. L. Streicher, and J. A. Mares Women's Health Initiative Diet Intervention Did Not Increase Macular Pigment Optical Density in an Ancillary Study of a Subsample of the Women's Health Initiative J. Nutr., September 1, 2009; 139(9): 1692 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Curran Celentano Where Do Eggs Fit in a Heart-Healthy Diet? American Journal of Lifestyle Medicine, July 1, 2009; 3(4): 274 - 278. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Zhao and B. V. Sweet Lutein and zeaxanthin for macular degeneration Am. J. Health Syst. Pharm., July 1, 2008; 65(13): 1232 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J Johnson, H.-Y. Chung, S. M Caldarella, and D M. Snodderly The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1521 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Borel, M. Moussa, E. Reboul, B. Lyan, C. Defoort, S. Vincent-Baudry, M. Maillot, M. Gastaldi, M. Darmon, H. Portugal, et al. Human Plasma Levels of Vitamin E and Carotenoids Are Associated with Genetic Polymorphisms in Genes Involved in Lipid Metabolism J. Nutr., December 1, 2007; 137(12): 2653 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Connor, P. B. Duell, R. Kean, and Y. Wang The Prime Role of HDL to Transport Lutein into the Retina: Evidence from HDL-Deficient WHAM Chicks Having a Mutant ABCA1 Transporter Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4226 - 4231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Waters, R. M. Clark, C. M. Greene, J. H. Contois, and M. L. Fernandez Change in Plasma Lutein after Egg Consumption Is Positively Associated with Plasma Cholesterol and Lipoprotein Size but Negatively Correlated with Body Size in Postmenopausal Women J. Nutr., April 1, 2007; 137(4): 959 - 963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. S. Aleman, A. V. Cideciyan, E. A. M. Windsor, S. B. Schwartz, M. Swider, J. D. Chico, A. Sumaroka, A. Y. Pantelyat, K. G. Duncan, L. M. Gardner, et al. Macular Pigment and Lutein Supplementation in ABCA4-Associated Retinal Degenerations Invest. Ophthalmol. Vis. Sci., March 1, 2007; 48(3): 1319 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bhosale, D. Y. Zhao, and P. S. Bernstein HPLC Measurement of Ocular Carotenoid Levels in Human Donor Eyes in the Lutein Supplementation Era Invest. Ophthalmol. Vis. Sci., February 1, 2007; 48(2): 543 - 549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Khachik, F. F. de Moura, E. Y. Chew, L. W. Douglass, F. L. Ferris III, J. Kim, and D. J. S. Thompson The Effect of Lutein and Zeaxanthin Supplementation on Metabolites of These Carotenoids in the Serum of Persons Aged 60 or Older Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5234 - 5242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Khachik, E. London, F. F. de Moura, M. Johnson, S. Steidl, L. DeTolla, S. Shipley, R. Sanchez, X.-Q. Chen, J. Flaws, et al. Chronic Ingestion of (3R,3'R,6'R)-Lutein and (3R,3'R)-Zeaxanthin in the Female Rhesus Macaque Invest. Ophthalmol. Vis. Sci., December 1, 2006; 47(12): 5476 - 5486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R Trumbo and K. C Ellwood Lutein and zeaxanthin intakes and risk of age-related macular degeneration and cataracts: an evaluation using the Food and Drug Administration's evidence-based review system for health claims. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 971 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A Mares, T. L LaRowe, D M. Snodderly, S. M Moeller, M. J Gruber, M. L Klein, B. R Wooten, E. J Johnson, R. J Chappell, and for the CAREDS Macular Pigment Study Group and Inv Predictors of optical density of lutein and zeaxanthin in retinas of older women in the Carotenoids in Age-Related Eye Disease Study, an ancillary study of the Women's Health Initiative. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 1107 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Goodrow, T. A. Wilson, S. C. Houde, R. Vishwanathan, P. A. Scollin, G. Handelman, and R. J. Nicolosi Consumption of One Egg Per Day Increases Serum Lutein and Zeaxanthin Concentrations in Older Adults without Altering Serum Lipid and Lipoprotein Cholesterol Concentrations J. Nutr., October 1, 2006; 136(10): 2519 - 2524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Wenzel, C. Gerweck, D. Barbato, R. J. Nicolosi, G. J. Handelman, and J. Curran-Celentano A 12-Wk Egg Intervention Increases Serum Zeaxanthin and Macular Pigment Optical Density in Women J. Nutr., October 1, 2006; 136(10): 2568 - 2573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Whitehead, J. A. Mares, and R. P. Danis Macular Pigment: A Review of Current Knowledge Arch Ophthalmol, July 1, 2006; 124(7): 1038 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. J. M. Berendschot and D. van Norren Macular Pigment Shows Ringlike Structures Invest. Ophthalmol. Vis. Sci., February 1, 2006; 47(2): 709 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. M. Ducreux, W. L. Morris, P. E. Hedley, T. Shepherd, H. V. Davies, S. Millam, and M. A. Taylor Metabolic engineering of high carotenoid potato tubers containing enhanced levels of {beta}-carotene and lutein J. Exp. Bot., January 1, 2005; 56(409): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Ribaya-Mercado and J. B. Blumberg Lutein and Zeaxanthin and Their Potential Roles in Disease Prevention J. Am. Coll. Nutr., December 1, 2004; 23(suppl_6): 567S - 587S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Neuringer, M. M. Sandstrom, E. J. Johnson, and D. M. Snodderly Nutritional Manipulation of Primate Retinas, I: Effects of Lutein or Zeaxanthin Supplements on Serum and Macular Pigment in Xanthophyll-Free Rhesus Monkeys Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 3234 - 3243. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L Molldrem, J. Li, P. W Simon, and S. A Tanumihardjo Lutein and {beta}-carotene from lutein-containing yellow carrots are bioavailable in humans Am. J. Clinical Nutrition, July 1, 2004; 80(1): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hartmann, P. A Thurmann, V. Spitzer, W. Schalch, B. Manner, and W. Cohn Plasma kinetics of zeaxanthin and 3'-dehydro-lutein after multiple oral doses of synthetic zeaxanthin Am. J. Clinical Nutrition, March 1, 2004; 79(3): 410 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Nelson, P. S. Bernstein, M. C. Schmidt, M. S. Von Tress, and E. W. Askew Dietary Modification and Moderate Antioxidant Supplementation Differentially Affect Serum Carotenoids, Antioxidant Levels and Markers of Oxidative Stress in Older Humans J. Nutr., October 1, 2003; 133(10): 3117 - 3123. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
